Brodalumab, a monoclonal antibody that targets the interleukin (IL)-17 receptor, was effective in moderate-to-severe plaque psoriasis in a phase III study, Amgen and AstraZeneca announced.
The trial's primary endpoint, a 75% improvement in the Psoriasis Area Severity Index (PASI 75) at week 12,
was achieved by 83.3% of patients receiving a higher dose of brodalumab and by 60.3% of those given a lower dose, compared with 2.7% of patients on placebo.
In addition, the percentage of patients who had at least 90% improvement were 70.3%, 42.5%, and 0.9% in the three groups, respectively, while 41.9%, 23.3%, and 0.5% showed 100% improvement.
Brodalumab is a human monoclonal antibody that inhibits inflammatory signaling through the IL-17 pathway.
The trial, known as AMAGINE-1, included 661 patients who initially were randomized to receive subcutaneous brodalumab in dosages of 210 mg or 140 mg or placebo every 2 weeks...
